- CNW Group•18 days agoResverlogix Announces Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208)
Resverlogix Announces Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208)
- PR Newswire•18 days agoResverlogix Announces Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208)
A data review by the independent Data Safety Monitoring Board resulted in a verbal recommendation for the BETonMACE trial to continue as planned without any modification. CALGARY, Aug. 11, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (RVX.TO) today announced that the independent Data and Safety Monitoring Board (DSMB) for the Company's Phase 3 BETonMACE trial in high-risk cardiovascular (CVD) patients has completed a planned safety review and verbally recommended that the study should continue as planned without any modifications. The DSMB reviewed available study data and noted that no safety or efficacy concerns were identified.
- Marketwired•25 days ago
With its lead drug candidate apabetalone already in Phase 3 targeting major adverse cardiac events, Resverlogix Corp. has expanded its scope by initiating a Phase 1 study of the small molecule to further ...
Resverlogix Corp. (RVX.TO)
Toronto - Toronto Delayed Price. Currency in CAD
|Day's Range||1.22 - 1.27|
|52wk Range||1.10 - 2.52|
|1y Target Est||N/A|
|P/E Ratio (ttm)||-6.41|
|Avg Vol (3m)||18,209|
|Dividend & Yield||N/A (N/A)|